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drome characterised by evidence of symptoms and/or signs 
of heart failure, left ventricular (LV) diastolic dysfunction, 
and -by definition- a preserved LV systolic function [1]. 
Although symptoms and signs of HFpEF are non-specific, 
individuals almost always present with dyspnoea on exertion 
and impaired exercise tolerance. While most clinical signs 
and symptoms in heart failure with preserved and reduced 
LV function are quite similar, individuals with HFpEF are 
more often older, predominantly female and are more likely 
to present with comorbidities, such as hypertension, obesity, 
diabetes, atrial fibrillation and renal disease [2, 3]. The exact 
pathophysiological mechanisms behind HFpEF are not fully 
understood, but likely to be multifactorial. LV diastolic dys-
function is the cornerstone process, but other factors may 
contribute to heart failure in these patients, including altered 
ventricular-arterial coupling, chronotropic incompetence, 
coronary artery disease, coronary microvascular rarefac-
tion, fibrosis and even subtle systolic dysfunction [4–7]. In 
addition, non-cardiac comorbidities such as pulmonary dis-
ease, anaemia, renal dysfunction or obesity may, at least in 
part, be responsible for the symptoms of heart failure.
HFpEF currently accounts for approximately 50 % of 
new heart failure cases and its prevalence relative to heart 
failure with reduced ejection fraction (HFrEF) is increas- 
ing [8, 9]. Furthermore, unlike previously thought, mor-
bidity and survival rates among patients with HFpEF are 
as ominous as for their counterparts with reduced ejec-
tion fraction [2]. Despite these worrisome trends, no sig-
nificant improvements in therapeutic strategies for HFpEF 
have been established [9]. Part of the explanation as to 
why results of therapeutic trials focusing on HFpEF have 
been disappointing thus far might be related to large differ-
ences in the underlying pathophysiological profile in these 
patients, which may have led to the inclusion of a hetero-
genic group of patients at different stages of the disease. 
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Abstract Heart failure with preserved ejection fraction 
(HFpEF) is a growing healthcare burden worldwide and its 
prevalence is increasing. Diagnosing HFpEF is challenging 
and relies upon the presence of symptoms and/or signs of 
heart failure, preserved left ventricular systolic function, 
and evidence of diastolic dysfunction. Current diagnostic 
algorithms mainly rely on echocardiography (E/e’) and 
biomarkers (NT-proBNP). However, only a minority of pa-
tients with HFpEF are identified, and especially HFpEF pa-
tients at an early stage of the disease are easily missed. We 
propose to incorporate invasive stress testing, by means of 
right heart catheterisation at rest and during exercise, and 
accurate assessment of right ventricular function, by means 
of cardiac magnetic resonance imaging. These additions to 
the current diagnostic work-up will improve diagnostic 
sensitivity and accurate staging of HFpEF patients.
Keywords Heart failure · Diastole · Diagnosis · 
Echocardiography · Exercise test · Swan-Ganz 
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Heart failure with preserved ejection fraction
Heart failure with preserved ejection fraction (HFpEF, pre-
viously described as diastolic heart failure) is a clinical syn-
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Current diagnostic algorithms
Up to now, four guidelines reporting on diagnosing HFpEF 
have been published [1, 13–15]. We will mainly discuss the 
guideline by Paulus et al. [1] as it is the most recent and 
most often cited.
Following this guideline, patients have to fulfil three cri-
teria: signs and/or symptoms of heart failure, no impaired 
systolic LV function (LV ejection fraction > 50 % and 
indexed LV end-diastolic volume < 97 ml/m²) and evi-
dence of LV diastolic dysfunction. Regarding evidence of 
diastolic dysfunction, the guideline by Paulus et al. states 
that either invasive haemodynamic measurements (pulmo-
nary capillary wedge pressure (PCWP) > 15 mmHg or LV 
end-diastolic pressure > 12 mmHg at rest) or tissue Doppler 
measurements (E/e’ >15) provide sufficient stand-alone evi-
dence of diastolic dysfunction. E/e’ in the range of 8–15 or 
high NT-pro B-type natriuretic peptide (NT-proBNP) levels 
(> 220 pg/ml; or BNP > 200 pg/ml) need to be accompa-
nied by at least one additional sign of diastolic dysfunction, 
including a low E/A ratio combined with a high deceleration 
time, pulmonary venous flow patterns suggestive of dia-
stolic dysfunction, high indexed left atrial volume, the pres-
ence of atrial fibrillation, and/or LV hypertrophy (Fig. 1).
So far, validation of the above-mentioned guidelines 
in large populations is limited, especially in patients at an 
early stage of HFpEF, where resting filling pressures are still 
Careful inclusion of HFpEF patients according to their 
stage of the disease, rather than considering HFpEF patients 
as one homogeneous group, might help to overcome this 
problem.
HFpEF: a diagnostic challenge
Although HFpEF poses a significant burden on health-
care systems worldwide, many questions regarding the 
best diagnostic approach remain unanswered. Diagnosing 
HFpEF is often a clinical challenge and this holds especially 
true for outpatients at an early stage of the disease without 
overt signs of heart failure [10, 11]. At that point the diag-
nosis is easily missed, as a normal ejection fraction and no 
evident signs of fluid retention may shift attention towards 
other causes of dyspnoea, such as pulmonary disease, obe-
sity or even deconditioning. Additionally, the fact that spe-
cific treatment for this disease is lacking, that symptoms are 
often nonspecific, and that current non-invasive markers of 
diastolic dysfunction especially lack sufficient sensitivity, 
may enhance the tendency to under-diagnose this disease 
even more [11–13]. In this review, we will discuss current 
diagnostic algorithms, and argue for a wider use of invasive 
stress testing.
Fig. 1 How to diagnose HFpEF. 
We propose ‘elevated PCWP dur-
ing exercise’ as a new criterion 
for (early) HFpEF. LVEF left 
ventricular ejection fraction, 
LVEDVi indexed left ventricular 
end-diastolic volume, PWCP 
pulmonary capillary wedge pres-
sure, dec.time deceleration time, 
LAVi indexed left atrial volume, 
LVMi indexed left ventricular 
mass, LVEDP left ventricular 
end-diastolic pressure
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cardiographic indices of diastolic dysfunction and therefore 
yields more accurate estimations of filling pressures.
To date, an elevated E/e’ (reflecting filling pressures 
> 15 mmHg) is incorporated in guidelines as sufficient evi-
dence of diastolic dysfunction [1]. Evidence supporting this 
approach comes from a study conducted by Ommen et al. 
[20]. Although in that study the correlation coefficient of 
E/e’ and mean LV filling pressures was only 0.47, all patients 
with a E/e’ >15 had high invasively assessed filling pressures, 
suggesting an excellent specificity of E/e’. Furthermore, 
other authors stated good correlations of E/e’ and invasively 
assessed LV filling pressures [21–23]. In contrast, it has 
been found that the correlation between E/e’ and PCWP may 
be worse than previously reported, albeit in either acutely 
decompensated patients with systolic dysfunction (LVEF 
< 30 %), [24] or symptomatic patients with hypertrophic car-
diomyopathy [25]. Also, it has been shown that changes in 
filling pressures over time in individual patients do not corre-
late with changes in E/e’, hampering the use of E/e’ as a tool 
to monitor individual patients during their disease course or 
monitor their response to therapy [18].
Although signs of diastolic dysfunction in terms of an 
elevated E/e’ >15 seem sufficient to detect elevated LV 
pressures in the initial assessment of patients suspected of 
HFpEF, filling pressures are variable over time, depending 
on volume status. Moreover, filling pressures might not be 
elevated in an early stage of the disease, as demonstrated 
by a study by Penicka et al. [11]. They found that in 30 % 
of stable outpatients with unexplained dyspnoea, invasively 
proven to have HFpEF, E/e’ indices were normal. Further-
more, only 25 % of HFpEF patients fulfilled the current defi-
nition of HFpEF and 20–40 % of controls had borderline 
E/e’ values, suggesting both low specificity and sensitivity 
for E/e’, even in combination with additional echo markers 
of diastolic dysfunction. Santos et al. recently reported that 
E/e’ could not accurately estimate PCWP, as demonstrated 
by Bland-Altman analysis and they showed that E/e’ did not 
accurately reflect changes in PCWP during alterations in 
loading conditions [26].
Taking into account the last-mentioned studies that have 
called the utility of E/e’ into question, [11, 26] it seems that 
E/e’ is not sensitive enough to detect HFpEF in outpatients 
with unexplained dyspnoea in an early stage of the dis-
ease, when impairments in diastole are less prominent. The 
absence of an elevated E/e’ therefore does not rule out the 
presence of diastolic dysfunction.
Biomarkers: value of BNP or NT-proBNP in 
diagnostic process
BNP is predominately produced by ventricular myocar-
dium and its release is stimulated by ventricular wall stress. 
normal. Next, we will discuss the usefulness and the most 
important drawbacks of the proposed non-invasive mea-
surements for diastolic dysfunction.
Echocardiography: its role in diagnosing HFpEF
Echocardiography has a pivotal role in the diagnostic process 
of HFpEF and is generally considered one of the most useful 
tests in this setting. It is readily available, provides informa-
tion on general cardiac anatomy and it allows the estimation 
of filling pressures combined with good spatial and tempo-
ral resolution. Provided diastolic dysfunction is the hallmark 
pathophysiological process in HFpEF, it is not surprising 
that echocardiography in HFpEF mainly focuses on mark-
ers of diastolic dysfunction. However, as echocardiographic 
parameters of diastolic dysfunction are influenced by heart 
rate and loading conditions, the main question is whether 
echocardiography, and Doppler parameters in particular, are 
suitable for assessing diastolic dysfunction.
Besides E/e’, which will be discussed below, echocardio-
graphic indices of diastolic dysfunction include E/A ratio, 
deceleration time of E, pulmonary venous flow assessment, 
left atrial (LA) volumes and LV mass [1]. Their usefulness 
in the diagnostic approach of patients suspected of HFpEF 
is narrowed to patients with an inconclusive E/e’ (between 
8–15), as described previously. [12] E/A ratio as assessed by 
pulsed wave Doppler represents mitral valve filling velocities 
and it is directly dependent on the pressure gradient between 
the left atrium and left ventricle (e.g. atrioventricular pres-
sure gradient). As a consequence, it is sensitive to both LA 
pressure and ventricular filling properties. However, due to 
the presence of pseudo normalisation and its preload depen-
dence, it is no longer advised to use it as stand-alone evidence 
for diastolic dysfunction. The validity and predictive value 
of the remaining blood flow Doppler derived markers of dia-
stolic dysfunction have been debated on by past authors and 
therefore the physiological principles and measuring tech-
niques fall beyond the scope of this review [16–19].
The key echocardiographic measurement in assessing 
diastolic dysfunction is E/e’. E represents peak velocity of 
transmitral flow in early diastole, as assessed by pulsed wave 
Doppler, whereas e’ represents either the early diastolic sep-
tal or lateral lengthening peak velocity of the mitral annulus, 
measured with tissue Doppler. As such, E is considered a 
reflection of the maximum pressure differences between the 
left atrium and left ventricle, and thus is mainly dependent 
on both ventricular relaxation and left atrial pressures. E’ is 
a reflection of the amount of blood entering the ventricle and 
mainly related to ventricular relaxation/LV filling pressures. 
E/e’ is thought to be a reflection of left atrial pressures and 
thus of left ventricular end-diastolic pressure. E/e’ is gener-
ally assumed to be less sensitive to preload than other echo-
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absence of elevated filling pressures at rest does not preclude 
patients from having profound haemodynamic impairments 
during exercise. Furthermore, filling pressures may be vari-
able over time, depending on volume status and physical 
activity. As such, the assessment of elevated filling pres-
sures non-invasively is far from an easy task.
Diastolic stress testing: why and how
Exercise testing has been shown to enhance the diagnosis of 
HFpEF in patients with no overt signs of volume overload 
and normal filling pressures at rest and it holds the most 
promise for novel diagnostic strategies [31].
In healthy subjects, exercise causes an increase in stroke 
volume, established by an increase in end-diastolic volume 
combined with a reduction in end-systolic volumes. As the 
heart rate increases as well, the left ventricle has less time 
to fill, whereas at the same time an elevated venous return 
causes an increase in volume loading. In healthy patients, 
a high diastolic reserve (the ability to increase myocardial 
relaxation under stress) prevents LV filling pressures from 
rising. In HFpEF, this normal diastolic reserve capacity 
is exhausted during exercise and LV filling pressures will 
increase (Fig. 2; [31, 32]). Additionally, a blunted increase 
in contractility during exercise has also been shown to play 
a role [33].
Up to now, various studies have reported on the use of 
exercise echocardiography (stress echocardiography) as 
a potential diagnostic tool [34–37]. Burgess et al. dem-
onstrated that in unselected patients undergoing left heart 
catheterisation, E/e’ during exercise correlates with inva-
sively measured LV filling pressures and that an elevated 
Consequently, elevated plasma levels of BNP (or its bio-
logically inactive form, NT-proBNP) directly reflect myo-
cardial stretch and are an indirect measure of elevated filling 
pressures. High BNP or NT-proBNP levels are proven to 
be correlated with high filling pressures and severity of 
diastolic dysfunction, [27] and are a strong predictor of 
outcome [28]. Despite levels being lower in patients with 
HFpEF than in HFrEF, NT-proBNP is generally considered 
to be of value in the routine diagnostic work-up in patients 
with preserved ejection fractions [1]. However, NT-proBNP 
levels are also influenced by tachycardia, atrial fibrillation, 
myocardial ischaemia, obesity or renal dysfunction, yield-
ing low specificity for this marker [29]. In addition, it is 
known that patients with near-normal or mildly elevated fill-
ing pressures can present with normal NT-proBNP levels 
[28, 30], and NT-proBNP also fails to reflect elevated fill-
ing pressures in patients who merely present with elevated 
filling pressures during exercise [11]. As such, although in 
contrast with the latest guideline, [1] we do not recommend 
using low NT-proBNP measures to exclude HFpEF, nor do 
we propagate elevated NT-proBNP levels as isolated evi-
dence of diastolic dysfunction. The preferred approach is 
always to combine levels of NT-proBNP with additional 
measures of diastolic dysfunction.
Diagnosing HFpEF: the value of invasive stress 
testing
In a significant proportion of patients with high clinical 
suspicion of HFpEF, previously described non-invasive 
measures are not sufficient to account for the presence 
of significant LV diastolic dysfunction. Importantly, the 
KEY MESSAGE  Invasive measurements during exercise can be helpful in unmasking signi	cant diastolic impairment (early HFpEF).
Fig. 2 At rest, left ventricular 
filling pressures might be normal 
(LVEDP or PCWP < 15 mmHg), 
even though the left ventricular 
end-diastolic pressure-volume 
relationship is already disturbed/
steepened. Invasive measure-
ments during exercise can be 
helpful in unmasking significant 
diastolic impairment (early 
HFpEF)
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Additional role for CMR
Over the last decade, attention has been given to the poten-
tial utility of cardiac magnetic resonance imaging (CMR) 
and it is among the most promising non-invasive modali-
ties. It provides excellent spatial resolution, and allows 
the assessment of global and regional cardiac anatomy. It 
is considered the clinical gold standard for measuring LV 
volumes and function, including LV hypertrophy. Further-
more, left atrial volume and function, blood flow velocities, 
as well as information on myocardial tissue characteristics 
such as T1-mapping to quantify the degree of diffuse myo-
cardial fibrosis, can be obtained [41–44].
In addition, CMR is also considered the gold standard 
for the assessment of the right ventricle [45]. Patients with 
HFpEF are at risk of developing pulmonary hypertension 
and thus right heart failure, as the right ventricle seems 
especially sensitive to alterations in afterload [46]. There-
fore, CMR might help to risk stratify HFpEF patients, espe-
cially when echocardiography yields inconclusive results.
Staging of HFPEF and the potential therapeutic 
consequences
Up to now, almost all HFpEF trials yielded either negative 
or inconclusive results. Advanced phenomapping tech-
niques were able to demonstrate that HFpEF is a hetero-
geneous disorder (three phenotypes were identified with 
distinct survival), [47] for which a one-size-fits-all approach 
is probably not the solution. This knowledge should be 
implemented in future diagnostic strategies for HFpEF. 
Evidence supporting this approach is limited, but can be 
derived from recent HFpEF trials. For instance, targeting 
HFpEF with the phosphodiesterase-5 inhibitor sildenafil 
had no effect on outcome in a large multicentre trial, [48] 
whereas a small study conducted in a specific HFpEF popu-
lation with advanced pulmonary vascular disease and right 
heart failure yielded beneficial results [49].
Conclusion/recommendations
The current diagnostic approach to HFpEF only identifies a 
minority of patients with HFpEF. We propose to incorporate 
invasive stress testing in the diagnostic work-up, by means 
of right heart catheterisation at rest and during exercise, and 
to include accurate assessment of RV function, by means 
of CMR. These additional measurements will not only 
help to identify patients with early HFpEF, but will also 
stage patients with advanced HFpEF accordingly, namely 
advanced HFpEF with and without pulmonary hyperten-
sion, and with or without right ventricular dysfunction. In 
E/e’ at exercise can help to identify patients with high fill-
ing pressures during exercise [35]. In contrast, Maeder et 
al. reported that peak exercise E/e’ did not significantly 
differ between HFpEF patients and controls, and that it 
did not correlate with right heart catheterisation derived 
PCWP during exercise [12]. On the other hand, exercise 
echocardiography may help to identify patients at high-
est risk of cardiac hospitalisation or death, since Donal 
et al. recently demonstrated that estimated pulmonary 
artery pressures by tricuspid regurgitation maximal veloc-
ity during exercise yield prognostic information in HFpEF 
patients [34].
One of the first studies addressing markedly elevated 
filling pressures during moderate exercise in patients with 
normal resting haemodynamics was by Borlaug et al. [31]. 
In that study, it became apparent that more than 50 % of 
patients with dyspnoea on exertion showed increased LV 
filling pressures merely during exercise. Results from this 
study suggest that measuring PCWP during a right heart 
catheterisation can help unmask the presence of diastolic 
dysfunction in patients with unexplained dyspnoea at an 
early stage of the disease. Corroborating these findings, 
Andersen et al. identified a significant increase in PCWP 
with exercise in 26 patients with either high filling pres-
sures at rest, or merely with exercise [38]. Interestingly, 
they directly compared haemodynamic responses to exer-
cise with acute volume loading and found that the former 
was the more sensitive manoeuvre to identify patients with 
exercised-induced HFpEF. The utility of invasive exercise 
testing is even more enhanced by the recent finding that an 
excessive rise in PCWP with exercise (‘early’ HFpEF) is 
associated with increased mortality rates [39].
Despite these studies providing adequate evidence of 
the utility of exercise measurements, it is currently not 
included in the guidelines as a standard approach [1]. As 
the utility of echocardiographic parameters during exer-
cise measures has been challenged and clear standardisa-
tion is lacking, [12] the use of invasively measured LV 
filling pressures during exercise is preferred and yields 
more robust information on haemodynamic derangements. 
Assessing filling pressures during right heart catheterisa-
tion is the favoured approach as it allows the simultane-
ous invasive assessment of pulmonary artery pressures, 
which can be used to further stratify patients. Furthermore, 
despite its invasive nature, right heart catheterisation is 
considered safe when performed at expert centres: mor-
bidity and mortality rates are 1.1 and 0.055 % respectively 
[40].
Taken together, we therefore propose to use invasive 
exercise testing to identify patients with HFpEF, when non-
invasive markers are inconclusive, no overt signs of fluid 
overload are present and clinical suspicion persists.
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